Abstract

Antibiotic allergies are reported by up to 1 in 4 cancer patients, almost 50% of which are considered low risk and precede the cancer diagnosis. We demonstrate the successful and safe implementation of a pilot oral penicillin challenge program for cancer patients with low-risk penicillin allergies, increasing the use of penicillin and narrow-spectrum beta-lactams post-testing.

Details

Title
The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study
Author
Trubiano, Jason A 1 ; Smibert, Olivia 2 ; Douglas, Abby 2 ; Devchand, Misha 3 ; Lambros, Belinda 2 ; Holmes, Natasha E 3 ; Chua, Kyra Y 3 ; Phillips, Elizabeth J 4 ; Slavin, Monica A 2 

 The National Centre for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Department of Infectious Diseases and Centre for Antibiotic Allergy and Research, Austin Health, Melbourne, Australia; Department of Medicine (Austin Health), University of Melbourne, Melbourne, Australia 
 The National Centre for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 
 Department of Infectious Diseases and Centre for Antibiotic Allergy and Research, Austin Health, Melbourne, Australia 
 Department of Infectious Diseases, Vanderbilt University Medical Centre, Nashville, Tennessee 
Publication year
2018
Publication date
Dec 2018
Publisher
Oxford University Press
e-ISSN
23288957
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3170953107
Copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.